{"id":600,"date":"2005-12-01T12:06:00","date_gmt":"2005-12-01T11:06:00","guid":{"rendered":"https:\/\/der-arzneimittelbrief.com\/artikel\/2005\/errata"},"modified":"2005-12-01T12:06:00","modified_gmt":"2005-12-01T11:06:00","slug":"errata","status":"publish","type":"post","link":"https:\/\/der-arzneimittelbrief.com\/artikel\/2005\/errata","title":{"rendered":"Errata"},"content":{"rendered":"<p>In einer Leserbriefbeantwortung (AMB 2005, 39, 80a) haben wir geschrieben, Imiquimod (Aldara\u00ae) sei zur Behandlung aktinischer Keratosen zugelassen. Das gilt f\u00fcr viele au\u00dfereurop\u00e4ische L\u00e4nder. Die EMEA hat das Pr\u00e4parat f\u00fcr diese Indikation noch nicht zugelassen. In der November-Ausgabe muss es in der Kl. Mitt. \u201eBukkal verabreichtes Midazolam\u2026\u201d (AMB 2005, 39, 87a) im 2. Absatz, letzte [&hellip;]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>In einer Leserbriefbeantwortung (AMB 2005, 39, 80a) haben wir geschrieben, Imiquimod (Aldara\u00ae) sei zur Behandlung aktinischer Keratosen zugelassen. Das gilt f\u00fcr viele au\u00dfereurop\u00e4ische L\u00e4nder. Die EMEA hat das Pr\u00e4parat f\u00fcr diese Indikation noch nicht zugelassen. In der November-Ausgabe muss es in der Kl. Mitt. \u201eBukkal verabreichtes Midazolam\u2026\u201d (AMB 2005, 39, 87a) im 2. Absatz, letzte [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[1342,1343],"class_list":["post-600","post","type-post","status-publish","format-standard","hentry","category-allgemein","tag-aktinische-keratosen","tag-imiquimod"],"_links":{"self":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/600","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/comments?post=600"}],"version-history":[{"count":0,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/600\/revisions"}],"wp:attachment":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/media?parent=600"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/categories?post=600"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/tags?post=600"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}